48 Trabectedin and lurbinectedin are effective against leukemic cells derived from patients affected by chronic and juvenile myelomonocytic leukemia

MLA

Alberto Zambelli, et al. “48 Trabectedin and Lurbinectedin Are Effective against Leukemic Cells Derived from Patients Affected by Chronic and Juvenile Myelomonocytic Leukemia.” European Journal of Cancer, vol. 50, Nov. 2014, p. 21. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........3fdf64817ea615c9caa8146e9f36982d&authtype=sso&custid=ns315887.

APA

Alberto Zambelli, Nicolò Panini, Carlos M. Galmarini, C. Cattrini, M. Della Porta, M. Romano, Vittorio Rosti, Richard Tancredi, Anna Gallì, M. D’Incalci, Luca Beltrame, Simonetta Andrea Licandro, Marco Zecca, Lara Paracchini, Eugenio Erba, S. Marchini, & Ezia Bello. (2014). 48 Trabectedin and lurbinectedin are effective against leukemic cells derived from patients affected by chronic and juvenile myelomonocytic leukemia. European Journal of Cancer, 50, 21.

Chicago

Alberto Zambelli, Nicolò Panini, Carlos M. Galmarini, C. Cattrini, M. Della Porta, M. Romano, Vittorio Rosti, et al. 2014. “48 Trabectedin and Lurbinectedin Are Effective against Leukemic Cells Derived from Patients Affected by Chronic and Juvenile Myelomonocytic Leukemia.” European Journal of Cancer 50 (November): 21. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........3fdf64817ea615c9caa8146e9f36982d&authtype=sso&custid=ns315887.